The majority of early-onset familial Alzheimer disease (AD) cases are caused by mutations in the highly related genes presenilin-1 (PS1) and presenilin-2 (PS1) and presinilin-2 (PS2) which encode what are predicted to be integral membrane proteins with six or eight membrane spanning domains. Because the presenilin mutations account for the majority of cases of inherited early onset forms of AD, understanding the normal function of the presenilins and how mutations in these proteins lead to Alzheimer disease are central questions in Alzheimer's research. In terms of AD, two aspects of presinilin activity have received particular attention. First, mutant presenilin has been shown to alter the relative levels of the longer and potentially more pathogenic amyloid Abeta peptide variants (i.e., Abeta1-42/43). Second, mutant presenilin has been shown to promote apoptosis. With regard to the role of presenilins in apoptosis, there is evidence suggesting that a protein-protein interaction between the COOH-terminus of PS2 and as yet unidentified protein(s) is responsible for activation for apoptosis. This proposal focuses on identifying and characterizing protein(s) which interacts with the COOH- terminus of the presenilins, mediating their effects on apoptosis and, possibly, on altering the relative levels of the longer Abeta variants.
The specific aims are as follows: 1) To identify and characterize proteins that interact with the COOH-terminus of the presenilins; 2) To study the role of interactor protein(s) in presenilin-mediated apoptosis; 3) To dissect the role of interactor protein(s) in presenilin-mediated increases in longer Abeta variants; and, 4) To elucidate the relationship between presinilin-mediated apoptosis and presenilin-mediated increases in longer Abeta variants.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG015801-04
Application #
6627928
Study Section
Special Emphasis Panel (ZRG1-MDCN-2 (01))
Program Officer
Snyder, Stephen D
Project Start
2000-02-01
Project End
2005-01-31
Budget Start
2003-03-01
Budget End
2005-01-31
Support Year
4
Fiscal Year
2003
Total Cost
$239,341
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Psychiatry
Type
Schools of Medicine
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Kou, Yan; Betancur, Catalina; Xu, Huilei et al. (2012) Network- and attribute-based classifiers can prioritize genes and pathways for autism spectrum disorders and intellectual disability. Am J Med Genet C Semin Med Genet 160C:130-42
Buxbaum, Joseph D (2004) A role for calsenilin and related proteins in multiple aspects of neuronal function. Biochem Biophys Res Commun 322:1140-4
Zaidi, Nikhat F; Thomson, Emma E; Choi, Eun-Kyoung et al. (2004) Intracellular calcium modulates the nuclear translocation of calsenilin. J Neurochem 89:593-601
Lilliehook, Christina; Bozdagi, Ozlem; Yao, Jun et al. (2003) Altered Abeta formation and long-term potentiation in a calsenilin knock-out. J Neurosci 23:9097-106
Lilliehook, C; Chan, S; Choi, E K et al. (2002) Calsenilin enhances apoptosis by altering endoplasmic reticulum calcium signaling. Mol Cell Neurosci 19:552-9
Choi, E K; Zaidi, N F; Miller, J S et al. (2001) Calsenilin is a substrate for caspase-3 that preferentially interacts with the familial Alzheimer's disease-associated C-terminal fragment of presenilin 2. J Biol Chem 276:19197-204
Osawa, M; Tong, K I; Lilliehook, C et al. (2001) Calcium-regulated DNA binding and oligomerization of the neuronal calcium-sensing protein, calsenilin/DREAM/KChIP3. J Biol Chem 276:41005-13
Buxbaum, J D; Lilliehook, C; Chan, J Y et al. (2000) Genomic structure, expression pattern, and chromosomal localization of the human calsenilin gene: no association between an exonic polymorphism and Alzheimer's disease. Neurosci Lett 294:135-8